Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Weighted Blanket to Improve Sedation and Comfort During Ventilator Weaning

13. Juli 2026 aktualisiert von: Jennifer Cahill, Massachusetts General Hospital

A Randomized Controlled Trial of a Hospital-Grade Weighted Blanket to Improve Sedation Quality During Ventilator Weaning in the Blake 7 MICU (MGH)

Patients in the ICU who are being taken off of a breathing machine (ventilator weaning) commonly experience anxiety, agitation, sleep disruption, and physiologic stress. Weighted blankets have been used to improve patient comfort; however, the design of standard weighted blankets can interfere with the ICU environment and are often not adaptable to individual patient needs. This study will evaluate a weighted blanket specifically designed for ICU use, with features that allow adjustable weight and flexible configuration (e. g., full body, shoulder, or lap).

This study aims to determine whether the ICU-adapted weighted blanket:

  • Improves sedation quality, measured using the Richmond Agitation-Sedation Scale (RASS), which is already part of routine ICU care
  • Helps patients stay in a light, comfortable level of sedation during ventilator weaning
  • Is safe, feasible, and acceptable for use in the ICU environment

Participants will be randomly assigned (like flipping a coin) to one of two groups:

  • Weighted blanket group, or
  • Standard linen group

Studienübersicht

Status

Anmeldung auf Einladung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

To help manage symptoms and discomfort while patients are being taken off of a breathing machine (ventilator weaning), patients are often treated with sedative medications to keep them calm or sleepy. While these medications are often necessary, they can sometimes lead to problems such as needing the breathing machine for longer, confusion (delirium), poor sleep, and longer stays in the ICU. Current ICU practice aims to use lighter levels of sedation when possible. As sedation is reduced, there is a need for safe, low-risk, non-medication approaches that help keep patients comfortable without affecting their alertness or breathing.

Previous studies suggest that weighted blankets may reduce anxiety and physiologic stress without negatively affecting vital signs. However, the standard design of commercially available weighted blankets can affect their safety and usability. These include materials and construction that are not ideal for hospital use, excessive heat retention, special washing requirements, limited ability to adjust blanket weight, and interference with medical lines, tubes, and equipment.

These observations, along with clinician feedback, informed the development of a hospital-grade weighted blanket designed specifically for ICU use. This weighted blanket allows the amount of weight to be adjusted (5-20 pounds) and can be applied in different ways (e. g., over the full body, on the shoulders, or on the lap) depending on patient needs. It is designed to work safely alongside standard hospital equipment and fits within routine ICU care.

This study will compare the use of this weighted blanket to standard hospital linens to understand whether this weighted blanket improves patient comfort. This study is a randomized controlled trial in which participants are randomly assigned to receive either (1) the weighted blanket or (2) standard hospital linens. The study will enroll 64 patients. Participants will remain in the study until removal of mechanical ventilation (extubation). All data collected are part of routine care, and patient care will not be altered by study participation.

The trial will take place at the Blake 7 Medical Intensive Care Unit at Massachusetts General Hospital.

Studientyp

Interventionell

Einschreibung (Geschätzt)

64

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Vereinigte Staaten
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02114
        • Massachusetts General Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Age ≥18 years
  • Intubated and mechanically ventilated
  • Receiving sedation and/or analgesia
  • Documented clinical decision to initiate ventilator weaning
  • Patient or legally authorized representative (LAR)/healthcare proxy (HCP) able to provide informed consent

Exclusion Criteria:

  • Conditions in which deep pressure / blanket application may compromise safety in the opinion of the treating clinical team
  • Braden Scale score ≤9 with evidence of significant skin compromise
  • Patients with pre-existing pressure injuries on posterior, weight-bearing body surfaces (e.g., sacrum, coccyx, heels) will be excluded
  • Recent major surgery or unstable fractures affecting the torso
  • Continuous prone positioning
  • Body mass index ≥35 kg/m² as a precautionary exclusion due to uncertainty regarding pressure distribution and respiratory mechanics during early feasibility testing
  • Concurrent enrollment in another interventional trial affecting sedation or ventilation
  • Anticipated withdrawal of life-sustaining therapy
  • Pregnant individuals in the 2nd or 3rd trimester

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Unterstützende Pflege
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Weighted blanket
The intervention group will receive the hospital-grade weighted blanket, to add on to usual care.
Gerät: Weighted blanket

For participants in the weighted blanket group:

  • ICU nursing staff will place a hospital grade weighted blanket on the patient during ventilator weaning
  • The blanket will weigh approximately 10% of the patient's body weight, with a maximum weight of 20 pounds.
  • The blanket's weight may be adjusted as needed. The blanket is composed of individual squares weighing about 5 pounds each. These squares can be attached to form composite blankets with total weights of 10, 15, or 20 pounds
  • The blanket may be used in different configurations (full body, shoulder, or lap) based on the patient's tolerance and the nursing staff's clinical judgment
  • The blanket does not restrict movement, airway access, or routine medical care
  • Nursing staff may remove the blanket at any time for comfort, safety, procedures, or clinical reasons
Schein-Komparator: Standard hospital linens
The control group will receive standard hospital bedding, which is part of usual care.
Gerät: Standard hospital linens

For participants in the standard hospital linens group:

  • Participants will receive standard hospital bedding during ventilator weaning. This is part of standard care for patients in the ICU
  • Bedding will be managed by ICU nursing staff according to routine clinical practice

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Sedation quality
Zeitfenster: Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.

Sedation and agitation will be measured using the Richmond Agitation-Sedation Scale (RASS). This scale ranges from +4 (combative) to -5 (unarousable), with 0 indicating an alert and calm state. Positive scores reflect agitation and negative scores reflect increasing levels of sedation.

Sedation quality is defined as the proportion of time patients spend within a goal RASS score, between 0 to +1, during ventilator weaning. This range reflects intended light sedation during ventilator weaning to preserve alertness and respiratory drive.
Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Acceptability of study
Zeitfenster: From initiation of ventilator weaning until extubation, assessed for up to two weeks.
Acceptability will be defined as less than or equal to 33% blanket rejection rate by patients. Blanket rejection will consist of patient or clinician request for the blanket to be permanently removed.
From initiation of ventilator weaning until extubation, assessed for up to two weeks.
Sedative and analgesic exposure
Zeitfenster: Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
Measured total amount of sedation and analgesia received from time weaning initiated to extubation, normalized per weight and time on study. Dose and frequency data will be derived from routine clinical documentation in the Epic Medication Administration Record (EPIC MAR).
Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
Time to extubation
Zeitfenster: From initiation of ventilator weaning until extubation, assessed for up to two weeks.
The time between ventilator weaning and extubation will be derived from Epic nursing flowsheets.
From initiation of ventilator weaning until extubation, assessed for up to two weeks.
Delirium incidence
Zeitfenster: Daily from initiation of ventilator weaning until extubation, assessed for up to two weeks.
Delirium will be assessed when RASS scores range between -1 to +1, using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). The CAM-ICU evaluates acute onset or fluctuating mental status, inattention, altered level of consciousness, and disorganized thinking. Delirium will be defined as present when features 1 and 2, plus either feature 3 or 4, are positive. Delirium incidence will be recorded as a binary outcome (present/absent) during the study period.
Daily from initiation of ventilator weaning until extubation, assessed for up to two weeks.
Pain severity
Zeitfenster: Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
Pain will be assessed using the Critical-Care Pain Observation Tool (CPOT) in patients unable to self-report. The tool includes four domains: facial expression, body movements, muscle tension, and compliance with the ventilator (or vocalization in non-intubated patients), each scored from 0 to 2 (total score 0-8). A CPOT score ≥3 will be considered indicative of clinically significant pain.
Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
Anxiety scores
Zeitfenster: Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
Anxiety/agitation level will be assessed using the Richmond Agitation-Sedation Scale (RASS). The RASS ranges from +4 (combative) to -5 (unarousable), with 0 indicating an alert and calm state. Positive scores reflect agitation and negative scores reflect increasing levels of sedation.
Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
ICU length of stay
Zeitfenster: From ICU admission until ICU discharge, assessed for up to one month.
The time between admission to the ICU and discharge from the ICU will be measured. This information will be derived from discharge documentation in Epic.
From ICU admission until ICU discharge, assessed for up to one month.
Incidence of new Grade 2 or higher pressure injury
Zeitfenster: Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
Safety event defined as development of a new Grade 2 or higher pressure injury. Pressure injury will be measured using the Braden Scale and by visual skin inspection. Risk factors are divided into six categories and are rated on a scale of 1 to 4. These measures are added up, and the total score indicates a patient's risk level for developing a pressure injury. A range between 19-23 indicates no risk, 15-18 indicates mild risk, 13-14 is a moderate risk, 10-12 is a high risk, and any number less than 9 is a severe risk.
Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
Incidence of sustained elevated core temperature
Zeitfenster: Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
Safety event defined as a core temperature greater than 100.4 degrees Fahrenheit (38 degrees Celsius) that persists of greater than or equal to 1 hour after blanket removal without alternative clinical explanation. Core temperature will be measured with standard Medical ICU temperature monitoring.
Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
Feasibility success
Zeitfenster: From study initiation until the last participant completes study participation, assessed for up to 1 year.
Feasibility success will be defined as achievement of both prespecified feasibility criteria: (1) enrollment of ≥50% of eligible participants and (2) collection of complete outcome data for ≥80% of enrolled participants. The outcome will be reported as whether the study met both feasibility criteria.
From study initiation until the last participant completes study participation, assessed for up to 1 year.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Massachusetts General Hospital

Ermittler

  • Hauptermittler: Jennifer E. Cahill, PhD, RN, Massachusetts General Hospital

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. August 2026

Primärer Abschluss (Geschätzt)

31. August 2027

Studienabschluss (Geschätzt)

31. Dezember 2027

Studienanmeldedaten

Zuerst eingereicht

2. Juli 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. Juli 2026

Zuerst gepostet (Tatsächlich)

17. Juli 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. Juli 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

13. Juli 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • 2026P000726

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Weighted blanket

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Greece

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

3
Abonnieren